Literature DB >> 17504841

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

G Bertsias1, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, D Isenberg, C G M Kallenberg, M Khamashta, J C Piette, M Schneider, J Smolen, G Sturfelt, A Tincani, R van Vollenhoven, C Gordon, D T Boumpas.   

Abstract

OBJECTIVE: Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. We sought to develop evidence-based recommendations addressing the major issues in the management of SLE.
METHODS: The EULAR Task Force on SLE comprised 19 specialists and a clinical epidemiologist. Key questions for the management of SLE were compiled using the Delphi technique. A systematic search of PubMed and Cochrane Library Reports was performed using McMaster/Hedges clinical queries' strategies for questions related to the diagnosis, prognosis, monitoring and treatment of SLE. For neuropsychiatric, pregnancy and antiphospholipid syndrome questions, the search was conducted using an array of relevant terms. Evidence was categorised based on sample size and type of design, and the categories of available evidence were identified for each recommendation. The strength of recommendation was assessed based on the category of available evidence, and agreement on the statements was measured across the 19 specialists.
RESULTS: Twelve questions were generated regarding the prognosis, diagnosis, monitoring and treatment of SLE, including neuropsychiatric SLE, pregnancy, the antiphospholipid syndrome and lupus nephritis. The evidence to support each proposition was evaluated and scored. After discussion and votes, the final recommendations were presented using brief statements. The average agreement among experts was 8.8 out of 10.
CONCLUSION: Recommendations for the management of SLE were developed using an evidence-based approach followed by expert consensus with high level of agreement among the experts.

Entities:  

Mesh:

Year:  2007        PMID: 17504841     DOI: 10.1136/ard.2007.070367

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  150 in total

Review 1.  Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  Connective tissue disease: Trial of SLE therapies in real-world settings.

Authors:  Manuel Ramos-Casals; Munther A Khamashta
Journal:  Nat Rev Rheumatol       Date:  2012-02-07       Impact factor: 20.543

3.  [Pregnancy and inflammatory rheumatic diseases].

Authors:  R Fischer-Betz; E Gromnica-Ihle
Journal:  Z Rheumatol       Date:  2010-09       Impact factor: 1.372

Review 4.  Biological therapy for lupus nephritis-tribulations and trials.

Authors:  Rona M Smith; Menna R Clatworthy; David R W Jayne
Journal:  Nat Rev Rheumatol       Date:  2010-07-20       Impact factor: 20.543

5.  Lupus: an overview of the disease and management options.

Authors:  William Maidhof; Olga Hilas
Journal:  P T       Date:  2012-04

6.  A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?

Authors:  Dimitrios T Boumpas; George K Bertsias; James E Balow
Journal:  Ann Rheum Dis       Date:  2010-12       Impact factor: 19.103

Review 7.  Belimumab: A Review in Systemic Lupus Erythematosus.

Authors:  Hannah A Blair; Sean T Duggan
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

8.  Toward electronic health recording: evaluation of electronic patient reported outcome measures (e-PROMs) system for remote monitoring of early systemic lupus patients.

Authors:  Y El Miedany; M El Gaafary; Nadia El Aroussy; S Bahlas; M Hegazi; D Palmer; S Youssef
Journal:  Clin Rheumatol       Date:  2017-05-31       Impact factor: 2.980

Review 9.  Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.

Authors:  Antonio Brucato; Rolando Cimaz; Roberto Caporali; Véronique Ramoni; Jill Buyon
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

Review 10.  [Systemic lupus erythematosus. Target criteria for treatment].

Authors:  T Alexander; R Biesen; A Jacobi; B Hoyer; A Bruns; F Hiepe
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.